Application Updates

INOvent Application Updates	English	French
High range calibration of the INOvent delivery system gas sensors	Update #1
Inspiratory gas sampling - overview	Update #2
Inspired gas sample management during aerosol delivery	Update #3
Inspiratory gas sampling in neonatal breathing systems	Update #4
Infrasonics infant star compatibility	Update #5
Connecting the INOvent delivery system to assorted breathing circuits	Update #6
Inspiratory gas sampling in Hudson RCI neonatal breathing systems	Update #7
Analysis of gases ina circle absorber system when using Nitric Oxide	Update #8	Update #8
Are environmental levels of NO and NO₂ a concern when using inhaled Nitrc Oxide	Update #9	Update #9
Use of nasal cannula with the INOvent delivery system	Update #10	Update #10
Sterilizing and Disinfection methods for INOvent delivery system	Update #11	Update #11
INOvent delivery system in extended transport with DC/AC inverters	Update #12	Update #12
INOvent delivery system and the Purtitan-Bennett Infant Star® 950 Ventilator in high frequency mode	Update #13	Update #13
Mechanical ventilators validated for use with Datex-Ohmeda INOvent delivery system	Update #14	Update #14 janviere Validated vents / aout validated vents
High Frequency Oscillatory (HFO) Ventilators validated with Datex-Ohmeda INOvent delivery system	Update #15	Update #15
INOvent delivery system and helium/oxygen (heliox) mixtures	Update #16	Update #16
Monitor failure during High Calibration of the INOvent	TB 07001-A
Old Calibration tubing tee– High Calibration Errors	TB 07002

© 2011 Ikaria, Inc.
INOMAX^® and INOvent^® are registered trademarks of INO Therapeutics LLC.
DS_IR^® is a registered trademark of Ikaria, Inc.

The product information provided in this site is intended only for residents of the United States.
The product discussed herein may have different product labeling in different countries.

INOMAX^® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

INOMAX Important Safety Information

INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Therefore, methemoglobin levels should be monitored during INOMAX administration. Caution should be used when administering INOMAX with other drugs that can cause methemoglobinemia regardless of their route of administration
Nitrogen dioxide (NO₂) rapidly forms in gas mixtures containing nitric oxide and oxygen. NO₂ formed in this way can cause airway inflammation and damage
INOMAX must be administered through a system that does not cause excessive generation of NO₂ and that monitors for NO, NO₂, and FiO₂
Abrupt discontinuation of INOMAX therapy can lead to worsening of PaO₂ and increasing pulmonary artery pressure (PAP). Deterioration in oxygenation and elevation in PAP can also occur in children with no apparent response to INOMAX
In patients with pre-existing left ventricular dysfunction, inhaled nitric oxide may increase pulmonary capillary wedge pressure leading to pulmonary edema

Please see Full Prescribing Information.

Refer a Colleague to INOMAX^®

Disclaimer

*Please note: When you access these resources, you are leaving the INOMAX website. Therefore, INOMAX and Ikaria Holdings Inc. do not endorse the accuracy of the information you may find. We encourage you to talk to your doctor about the accuracy of any information you discover through these Internet resources.

Agree and continue →

Application Updates

Refer a Colleague to INOMAX®

Get INOMAX® Email Updates

Disclaimer

Refer a Colleague to INOMAX^®

Get INOMAX^® Email Updates